Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.
JAMA Psychiatry April 2, 2025 Antonio Del Casale, Sara Spirito, Jan Francesco Arena et al. 17 citations
Treatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations' effectiveness in real-world settings is sparse. To determine...